Patents Represented by Attorney, Agent or Law Firm Daniel W. Collins
  • Patent number: 8173623
    Abstract: A process for the synthesis of bisfuran intermediates useful for preparing antiviral HIV protease inhibitor compounds is hereby disclosed.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: May 8, 2012
    Assignee: Gilead Sciences, Inc.
    Inventors: Kenneth R. Crawford, Eric Dowdy, Arnold Gutierrez, Richard P. Polniaszek, Richard Hung Chiu Yu
  • Patent number: 7566717
    Abstract: Disclosed are novel heterocyclic compounds having the structure which are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.
    Type: Grant
    Filed: July 9, 2008
    Date of Patent: July 28, 2009
    Assignee: Gilead Sciences, Inc.
    Inventors: Venkata Palle, Jeff Zablocki
  • Patent number: 6730796
    Abstract: This invention provides a process for preparing an N-substituted 2-sulfanylimidazole compound of the formula (I) by reacting an isothiocyanate of the formula R1NCS with an &agr;-aminocarbonyl compound of the formula NH2CHR4C(OP)2R3 and an alkyl halide or an activated aryl halide of the formula R2X in a solvent, alternatively, by reacting an isothiocyanate of the formula R1NCS with an &agr;-aminocarbonyl compound of the formula NH2CHR4C(OP)2R3 before adding an alkyl halide of the formula R2X, wherein R1 and R2 independently represent alkyl, heterocyclyl, aryl, or heteroaryl groups; R3 and R4 independently represent hydrogen, alkyl, heterocyclyl, aryl or heteroaryl or may form a non-aromatic ring; P represents a protecting group of a carbonyl group.
    Type: Grant
    Filed: April 14, 2003
    Date of Patent: May 4, 2004
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Jie Fei Cheng, Mi Chen
  • Patent number: 6642353
    Abstract: Clones isolated from phage display libraries that bound to an erythropoietin (EPO) receptor probe are disclosed. Peptides encoded by sequences of those clones that bound to the EPO receptor are disclosed. A 12-mer amino acid consensus sequence, CXXGWVGXCXXW (where X represents one of many amino acids), common to the peptides that bound to the EPO receptor, but unrelated to the primary structure of EPO, is disclosed.
    Type: Grant
    Filed: September 20, 2000
    Date of Patent: November 4, 2003
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Stephen J. McConnell, Dominic G. Spinella
  • Patent number: 6559140
    Abstract: Compounds of formula (I) compounds of formula (II) compounds of formula (III) and compounds of formula (IV) or pharmaceutically acceptable salts thereof are useful as H3 receptor antagonists. Processes to make the compounds and methods of treatment using the compounds are also disclosed.
    Type: Grant
    Filed: March 5, 2001
    Date of Patent: May 6, 2003
    Assignee: Abbott Laboratories
    Inventors: Youssef L. Bennani, Lawrence A. Black, Wesley J. Dwight, Ramin Faghih, Robert G. Gentles, Huaqing Liu, Kathleen M. Phelan, Anil Vasudevan, Henry Q. Zhang
  • Patent number: 6518430
    Abstract: The present invention relates to an efficient process for the preparation of 5-(substituted)-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinolines.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: February 11, 2003
    Assignee: Abbott Laboratories
    Inventors: Yi-Yin Ku, Timothy A. Grieme, Padam N. Sharma, Prasad S. Raje, Howard E. Morton, Mike A. Fitzgerald
  • Patent number: 6472545
    Abstract: Compounds of formula (I) or therapeutically acceptable salts thereof, are protein tyrosine kinase PTP1B inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed.
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: October 29, 2002
    Assignee: Abbott Laboratories
    Inventors: Gang Liu, Zhonghua Pei
  • Patent number: 6437138
    Abstract: Novel 3-pyridyloxymethyl heterocyclic ether compounds of the formula: or the pharmaceutically-acceptable salts or prodrugs thereof are selective and potent ligands at neuronal nicotinic cholinergic channel receptors, and are effective in controlling synaptic transmission. Key intermediates and processes using this key intermediates to produce compounds of formula I with the variables defined in the specification are also described.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: August 20, 2002
    Assignee: Abbott Laboratories
    Inventors: Nan-Horng Lin, Yun He, Mark W. Holladay, Keith Ryther, Yihong Li, Hao Bai
  • Patent number: 6436986
    Abstract: The instant invention relates to compounds of formula I which are useful as antagonists of the glucocorticoid receptor and for treating diabetes in a mammal. In addition, any glucocorticoid receptor antagonist(s) is useful for the treatment of diabetes.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: August 20, 2002
    Assignee: Abbott Laboratories
    Inventors: Philip R. Kym, Benjamin C. Lane, John K. Pratt, Tom von Geldern
  • Patent number: 6403575
    Abstract: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula I: or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula I above which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.
    Type: Grant
    Filed: July 19, 2000
    Date of Patent: June 11, 2002
    Assignee: Abbott Laboratories
    Inventors: Mark W. Holladay, Stephen P. Arneric, Hao Bai, Michael J. Dart, Nan-Horng Lin, John K. Lynch, Yat Sun Or, Keith B. Ryther, James P. Sullivan, James T. Wasicak, Paul P. Ehrlich
  • Patent number: 6355490
    Abstract: The present invention relates to a process of coding and identifying individual members of a chemical combinatorial library synthesized on a plurality of solid supports which undergo mix and split synthesis. The process provides for tagging the solid supports with a coding identifier that is attached to the solid support and which can be decoded by infrared or raman spectroscopy when directly attached to the support.
    Type: Grant
    Filed: September 4, 1997
    Date of Patent: March 12, 2002
    Inventors: Jill Edie Hochlowski, Thomas J. Sowin, Daniel W. Norbeck, Anne-Laure Marie Grillot, Rolf E. Swenson
  • Patent number: 6329534
    Abstract: Compounds of formula I are useful for treating type II diabetes, obesity, hyperglycemia, inadequate glucose clearance, hyperinsulinemia, hypertriglyceridemia, and high-circulating glucocorticoid levels, preparations of the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: December 11, 2001
    Assignee: Abbott Laboratories
    Inventors: Philip R. Kym, Benjamin C. Lane, John K. Pratt, Tom Von Geldern, Martin Winn, Jehrod Brenneman, Jyoti R. Patel, David L. Arendsen, Irini Akritopoulou-Zanze
  • Patent number: 6297021
    Abstract: X-ray crystallography can be used to screen compounds that are not known ligands of a target biomolecule for their ability to bind the target biomolecule. The method includes obtaining a crystal of a target biomolecule; exposing the target biomolecule crystal to one or more test samples; and obtaining an X-ray crystal diffraction pattern to determine whether a ligand/receptor complex is formed. The target is exposed to the test samples by either co-crystallizing a biomolecule in the presence of one or more test samples or soaking the biomolecule crystal in a solution of one or more test samples. In another embodiment, structural information from ligand/receptor complexes are used to design ligands that bind tighter, that bind more specifically, that have better biological activity or that have better safety profile. A further embodiment of the invention comprises identifying or designing biologically-active moieties by the instant process.
    Type: Grant
    Filed: March 5, 1999
    Date of Patent: October 2, 2001
    Assignee: Abbott Laboratories
    Inventors: Vicki L. Nienaber, Jonathan Greer, Celerino Abad-Zapatero, Daniel W. Norbeck
  • Patent number: 6274385
    Abstract: The present invention relates to a process of coding and identifying individual members of a chemical combinatorial library synthesized on a plurality of solid supports which undergo mix and split synthesis. The process provides for tagging the solid supports with a coding identifier that is attached to the solid support and which can be decoded by infrared or raman spectroscopy when directly attached to the support.
    Type: Grant
    Filed: August 9, 1999
    Date of Patent: August 14, 2001
    Assignee: Abbott Laboratories
    Inventors: Jill Edie Hochlowski, Thomas J. Sowin, Daniel W. Norbeck, Anne-Laure Marie Grillot, Rolf E. Swenson
  • Patent number: 6168913
    Abstract: The present invention relates to coding combinatorial chemical libraries synthesized on a plurality of solid supports by attaching “tags” that comprise fluorine containing compounds in combinations and/or ratios. The tags can be decoded while attached to the solid support by fluorine nuclear magnetic resonance spectroscopy to follow the reaction history of individual beads, and to determine the particular member of the library that is attached on the bead.
    Type: Grant
    Filed: October 14, 1997
    Date of Patent: January 2, 2001
    Assignee: Abbott Laboratories
    Inventors: Jill Edie Hochlowski, Thomas J. Sowin, Daniel W. Norbeck, Warren S. Wade, David N. Whittern
  • Patent number: 6121471
    Abstract: The invention is a catalyst, the use of the catalyst and a method of using the catalyst in the formation of a compound with an amide bond. The catalyst is an HOBT derivative having the following formula (1): ##STR1## where R.sup.1 is a group bearing a positive charge at pH 5-7; where Y is a bond or a substituted or unsubstituted alkylene chain containing 1-10 carbon atoms and 0-2 heteroatoms selected from the group consisting of N, S and O; and where X is a linker group selected from --CO-- or --SO.sub.2 --. In the method, an amine, a carboxylic acid, an amide coupling agent and a catalyst of formula (1) are reacted for a time sufficient to produce an amide bond between the amine and the carboxylic acid. Thereafter, the compound containing the amide bond is isolated.
    Type: Grant
    Filed: December 17, 1998
    Date of Patent: September 19, 2000
    Assignee: Eli Lilly and Company
    Inventor: William Leonard Scott
  • Patent number: 6080587
    Abstract: Methods for rapidly generating large rationally designed libraries of structurally-diverse small molecular weight compounds using a multicombinatorial approach.
    Type: Grant
    Filed: January 23, 1998
    Date of Patent: June 27, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Raymond Pavia, Harold Vernon Meyers
  • Patent number: 6075040
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: June 13, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Patent number: 5759865
    Abstract: This invention relates to a combinatorial process for synthesizing a library of azetidinone peptide-like compounds. The compounds are synthesized as mixtures from a common azetidinone intermediate. The compounds are biologically active as inhibitors of the Vasopressin (V1a) receptor.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: June 2, 1998
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Michael O. Chaney, Robin D. Cooper, David C. Hunden, Gary A. Koppel, Jeffrey J. Skelton
  • Patent number: 5693611
    Abstract: Provided are pharmaceutical formulations, and methods of inhibiting fungal and parasitic activity using a compound of formula I ##STR1## wherein: R', R", R'", R.sup.x1, R.sup.x2, R.sup.y1, R.sup.y2, R.sup.y3, R.sup.y4, and R.sup.0 are as defined herein below;R.sup.2 is a novel acyl side chain. Also provided are novel formulations and methods of inhibiting fungal and parasitic activity.
    Type: Grant
    Filed: January 17, 1997
    Date of Patent: December 2, 1997
    Assignee: Eli Lilly and Company
    Inventors: Stacy Kay Henle, William Wilson Turner